TomTom to provide Opel with semi-integrated connected navigation
TomTom today announces the introduction of TomTom Connect : a semi–integrated navigation solution tailored specifically to Opel and Vauxhall cars. This is the first time that drivers of these cars will have access to all the benefits of connected navigation .
TomTom Connect is neatly integrated in the car and provides a great navigation experience; offering LIVE Services, including TomTom HD Traffic and dynamic routing. It gives drivers the fastest route to their destination based on the latest traffic situation. The system software and content can be updated through the online portal MyTomTom.
“Opel and TomTom have been working closely together to offer Opel and Vauxhall drivers the full advantages of real time navigation services,” says Giles Shrimpton, Managing Director TomTom Automotive. “This is an important step in our relationship and I look forward to developing the opportunities this brings for both companies.”
TomTom Connect will be available on the following Opel and Vauxhall models: Astra J, Corsa D, Meriva B, Combo D, and Insignia via Opel and Vauxhall dealers as of December in Europe.
Key features
The key features of the new TomTom Connect include:
-
HD Traffic – a combination of real time traffic and unique dynamic
routing
- The real time traffic information is generated from a network of over 80 million probes in Europe
- It covers 99.9% of the road network, reports more traffic jams in real-time and is also refreshed more frequently than any other service
- One year LIVE Services included in 30 countries
- Up-to-date speed camera information on both fixed and mobile cameras en route
- Live weather updates and local search which is sent directly to your in-dash system
- The navigation solution can be easily updated; anything from maps, to new software can be downloaded to the device via MyTomTom
- Latest generation voice recognition
- Car specific and crash tested cradle, which automatically charges the PND
- Software customisation, including dealer POIs and specific vehicle icons
–END –
About TomTom
Founded in 1991, TomTom (AEX:TOM2) is the world’s leading supplier of in-car location and navigation products and services focused on providing all drivers with the world’s best navigation experience. Headquartered in Amsterdam, TomTom has over 3,500 employees and sells its products more than 40 countries.
Our products include portable navigation devices, in-dash infotainment systems, fleet management solutions, maps and real-time services, including the award winning TomTom HD Traffic.
For the world’s most up-to-date route planner, including live traffic information please visit www.tomtom.com/livetraffic
For further information, please visit www.tomtom.com
Follow us on Twitter @TomTomCorporate.com
Contact:
TomTom Contacts:
Corporate Communications
Kristina
Nilsson,
+31 20 757 5194
cc@tomtom.com
or
Investor
Relations
Richard Piekaar,
+31 20 757 5194
ir@tomtom.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 14:00:00 CEST | Press release
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #
SLB Announces First-Quarter 2025 Results; Remains Committed to Return a Minimum of $4 Billion to Shareholders in 202525.4.2025 12:50:00 CEST | Press release
Revenue of $8.49 billion decreased 3% year on year GAAP EPS of $0.58 decreased 22% year on year EPS, excluding charges and credits, of $0.72 decreased 4% year on year Net income attributable to SLB of $797 million decreased 25% year on year Adjusted EBITDA of $2.02 billion decreased 2% year on year Cash flow from operations of $660 million increased $333 million year on year Board approved quarterly cash dividend of $0.285 per share SLB (NYSE: SLB) today announced results for the first-quarter 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250423635499/en/ The exterior of the SLB headquarters in Houston, Texas. First-Quarter Results (Stated in millions, except per share amounts) Three Months EndedChange Mar. 31, 2025 Dec. 31, 2024 Mar. 31, 2024 Sequential Year-on-year Revenue $8,490 $9,284 $8,707 -9% -3% Income before taxes - GAAP basis $1,063 $1,387 $1,357 -23% -22% Income before taxes margin - GAAP basis 12.5% 14.9%
Corona, The World’s Most Valuable Beer Brand1, Announces Its 100-Year Anniversary with Global Celebration25.4.2025 10:00:00 CEST | Press release
Brand Invites The World to Join the Celebration with Experiences at the Most Epic Beaches on EarthGlobal “Corona 100” Platform Launches with a Legendary Concert at Copacabana Beach, Featuring One of the World’s Top Musical Artists with Millions in Attendance Today, Corona proudly celebrates its 100-year anniversary, a remarkable milestone for the iconic brand that has been synonymous with the beach and enjoyed by consumers worldwide for the past century. Since 1925, Corona has cultivated a deep association with the beach; fully embodying a lifestyle connected to nature and relaxation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425804516/en/ Corona 100 This Is Living Since 1925 In honor of the occasion, Corona invites everyone to live their “beach side” – a.k.a. their best side – at top-tier beach locations across the globe. The Corona 100 platform includes a film highlighting 100 years of beach culture, a definitive l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom